I Richard Garr Chief Executive Officer and General Counsel
I Richard Garr, J.D., was a Director, and Neuralstem’s Chief Executive Officer and President from 1996 through February of 2016. Additionally, as a co-founder and General Counsel at Neuralstem, Mr. Garr had responsibility and oversight for all operations of a world-leading regenerative medicine company developing cell and gene therapies, small molecule drugs and genomic database products. He was responsible for worldwide business development, joint ventures, and licensing, a worldwide intellectual property portfolio and among other firsts created the stem cell industry’s first development agreements for Korea, Indonesia, Singapore, Malaysia, and Vietnam.
In 2016, Mr. Garr became a full-time advocate for patient’s rights to access experimental treatments in development both in the U.S. and Europe. In 2018, he founded Access Hope CRO, the only CRO dedicated exclusively to facilitating safe, ethical, and legal expanded patient access to potentially life-saving investigational treatments under the Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act of 2018. Mr. Garr is a graduate of Drew University (1976) and the Columbus School of Law, The Catholic University of America (1979).
Additionally, he was a founder and is a current Board member of the First Star Institute, a children’s charity focused on abused children’s issues; a founder of The Starlight Foundation Mid-Atlantic chapter, which focuses on helping seriously ill children; and a past Honorary Chairman of the Brain Tumor Society.